2021-06-17 08:00
Preparations for the launch of DiviTum®TKa Significant events during the fourth quarter Significant events after the end of the period Audiocast: When: 18 June 2021 at 10.00 CET Where: https://tv.streamfabriken.com/biovica-international-q4-2020-2021...
2021-03-18 08:00
FDA resumes review of DiviTum®TKa submission Significant events during the third quarter Significant events after the end of the period Audiocast: When: 18 March 2021 at 10.00 CET Where: https://tv.streamfabriken.com/biovica-international-q3-2020-2021...
2020-12-03 08:00
Convincing study results and application submitted to the FDA - commercialization just around the corner Significant events during the second quarter · Clinical validation, which is the last step required for the FDA application, has been completed...
2020-08-27 08:00
Clinical validation completed, work with the FDA submission in the final phase Significant events during the fourth quarter Significant events after the end of the period CEO’s comments During the quarter, we took important steps towards achieving...
2020-06-05 08:00
Preparations for the launch of DiviTum® have started Significant events during the fourth quarter Significant events after the end of the period CEO’s comments Biovica has had yet another eventful quarter. We have focused our efforts on the...
2020-03-12 08:00
Significant events during the third quarter Significant events after the end of the period Audiocast When: 12 March 2020 at 10.00 CET Where: https://tv.streamfabriken.com/biovica-international-q3-2019-2020 or SE: +46850558352 / DK: +4578150110...
2019-12-05 08:00
Period: May-October 2019/2020 Significant events during the second quarter Significant events after the end of the period Audiocast When: 6 December 2019 at 10.00 CET
Where: https://tv.streamfabriken.com/biovica-international-q2-2019...
2019-08-29 08:00
Significant events during the first quarter Significant events after the end of the period CEO’s comments Commercialization of DiviTum® for breast cancer During the first quarter of the new financial year, we achieved several important milestones...
2019-06-14 08:00
Significant events during the fourth quarter Significant events after the end of the period CEO's comments Commercialization of DiviTum® for breast cancer During the fourth quarter, we achieved several important milestones for launching DiviTum®...
2019-03-21 08:00
CEO’s comments Continued focus on commercialization of DiviTum® The focus of Biovica’s business plan is commercialization of DiviTum®, which will provide cancer patients with more personalized treatments leading to better outcomes...
>4,500
Numbers of patients in studies
28
Publications
19
Pharma Projects